Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. The whole genome sequencing of different subtypes of leukemia has revealed new recurrent genetic and chromosomal abnormalities that add value to the existing prognostic scoring index in different subtypes of leukemia.
The scope of this B-ALL/T-ALL risk stratification gene panel testing includes screening a panel of 22 prognostically significant genes for mutations via next-generation sequencing (NGS).
Disclaimer:
In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.
Contains19 tests
Earliest reports in18 days
Samples requiredBlood
ForMen & women
Also known as
Acute Lymphoblastic Leukemia risk stratification
What does B-ALL Risk Stratification measure?
Package contains 19 tests
ABL1
ATRX
CDKN2A
CREBBP
DNMT3A
ETV6
FBXW7
FLT3
IKZF1
JAK2
KDM6A
KMT2D
NOTCH1
NOTCH2
PHF6
PTEN
RUNX1
HRAS
WT1
Samples required
BloodOur phlebotomist will draw a blood sample, typically from a vein in your inner elbow.
Preparations
Clinical history and Tata 1mg consolidated TRF are required.